Disc Medicine Gets FDA Commissioner's National Priority Voucher for Drug Candidate
MT Newswires Live
Oct 17
Disc Medicine (IRON) said late Thursday it has received Commissioner's National Priority Voucher, meant to expedite drug review process, from the US Food and Drug Administration for its drug candidate bitopertin.
The company is seeking an accelerated approval of bitopertin for the treatment of erythropoietic protoporphyria, a rare and potentially life-threatening disease that causes severe reactions when patients are exposed to sunlight.
The program is aimed to reduce the drug application review process to one to two months, the company added.
Shares of Disc Medicine were up 19% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.